Triclosan as a Systemic Antibacterial Agent in a Mouse Model of Acute Bacterial Challenge

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3859-3866

  Sharma, Shilpi ^a   Ramya, T N C ^a   Surolia, Avadhesha ^a   Surolia, Namita ^b  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; TETRACYCLINE; TRICLOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BLOOD ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LIVER INJURY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL TIME;

ACUTE DISEASE; AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTEREMIA; BLOOD CHEMICAL ANALYSIS; ESCHERICHIA COLI INFECTIONS; LIVER; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PENICILLINS; TETRACYCLINE; TRICLOSAN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344875058     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3859-3866.2003     Document Type: Article

References (43)

1. Bhargava, H. N., and P. A. Leonard. 1996. Triclosan: applications and safety. Am. J. Infect. Control 24:209-218.
2. Bowers, L. D. 1980. Kinetic serum creatinine assays. I. The role of various factors in determining specificity. Clin. Chem. 26:551-554.
3. Bowers, L. D., and E. T. Wong. 1980. Kinetic serum creatinine assays. II. A critical evaluation and review. Clin. Chem. 26:555-561.
4. Decker, K., and D. Keppler. 1974. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol. Biochem. Pharmacol. 71:77-106.
5. DeSalva, S. J., B. M. Kong, and Y. J. Lin. 1989. Triclosan: a safety profile. Am. J. Dent. 2:185-196.
6. Dumas, B. T., W. A. Watson, and H. G. Biggs. 1971. Albumin standards and the measurement of serum albumin with bromocresol green. Clin. Chim. Acta 258:21-30.
7. Dyatkina, N. B., C. D. Roberts, J. D. Keicher, Y. Dai, J. P. Nadherny, W. Zhang, U. Schmitz, A. Kongpachith, K. Fung, A. A. Novikov, L. Lou, M. Velligan, A. A. Khorlin, and M. S. Chen. 2002. Minor groove DNA binders as antimicrobial agents. 1. Pyrrole tetraamides are potent antibacterials against vancomycin resistant Enterococci [corrected] and methicillin resistant Staphylococcus aureus. J. Med. Chem. 45:805-817.
8. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76:5939-5943.
9. Hay, A. G., P. M. Dees, and G. S. Sayler. 2001. Growth of a bacterial consortium on triclosan. FEMS Microbiol. Ecol. 36:105-112.
10. Heath, R. J., S. W. White, and C. O. Rock. 2002. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58:695-703.
11. Heath, R. J. 2001. Bacterial fatty-acid biosynthesis: an antibacterial drug target waiting to be exploited. Drug Discov. Today 6:715.
12. Heath, R. J., L. Jing, G. E. Roland, and C. O. Rock. 2000. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 275:4654-4659.
13. Heath, R. J., J. R. Ronald, D. R. Holland, E. Zhang, M. E. Snow, and C. O. Rock. 1999. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274:11110-11114.
14. Heath, R. J., Y. Yuen-Tsu, M. A. Shapiro, E. Olson, and C. O. Rock. 1998. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273:30316-30320.
15. Hogan, M. M., and S. N. Vogel. 1990. Measurement of TNF-alpha and beta, unit 6.10. In J. E. Coligan et al. (ed.), Current protocols in immunology, vol. 1. John Wiley & Sons, New York, N.Y.
16. Kanamaru, T., Y. Nakano, Y. Toyoda, K.-I. Miyagawa, M. Tada, T. Kaisho, and M. Nakao. 2001. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob. Agents Chemother. 45:2455-2459.
17. Kapoor, M., M. J. Dar, A. Surolia, and N. Surolia. 2001. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 289:832-837.
18. Karmen, A., F. Wroblewski, and J. S. Ladue. 1954. Transaminase activity in human blood. J. Clin. Investig. 33:131.
19. Keppler, D., R. Lesch, W. Reutter, and K. Decker. 1968. Experimental hepatitis induced by D-galactosamine. Exp. Mol. Pathol. 9:279-290.
20. Lacy, M. K., D. P. Nicolau, M. A. Banevicius, C. H. Nightingale, and R. Quintiliani. 1999. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model. J. Antimicrob. Chemother. 44:477-481.
21. Lyman, F. L., and T. Furia. 1969. Toxicology of 2,4,4′ -trichloro-2′-hydroxydiphenyl ether. Ind. Med. 38:45-52.
22. Milano, S., F. Arcoleo, P. D'Agostino, and E. Cillari. 1997. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob. Agents Chemother. 41:117-121.
23. Mitruka, M., and H. M. Rawnsley. 1977. Clinical, biochemical and hematological reference values in normal experimental animals. Mason Publishing, New York, N.Y.
24. Mitten, M. J., J. Meulbroek, M. Nukkala, L. Paige, K. Jarvis, A. Oleksijew, A. Tovcimak, L. Hernandez, J. D. Alder, P. Ewing, Y. S. Or, Z. Ma, A. M. Nilius, K. Mollison, and R. K. Flamm. 2001. Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob. Agents Chemother. 45:2585-2593.
25. Morita, Y. S., K. S. Paul, and P. T. Englund. 2000. Specialized fatty acid synthesis in African trypanosomes: myristate for GPI anchors. Science 288: 140-143.
26. Reitman, S., and S. Frankel. 1957. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 28:56.
27. Rock, C. O., and J. E. Cronan. 1996. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Biochim. Biophys. Acta 1302:1-16.
28. Saugar, J. M., T. Alarcón, S. López-Hernandez, M. López-Brea, D. Andreu, and L. Rivas. 2002. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob. Agents Chemother. 46:875-878.
29. Shapira, L., W. A. Soskolne, Y. Houri, V. Barak, A. Halabi, and A. Stabholz. 1996. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect. Immun. 64:825-828.
30. Slater-Radosti, C., G. Van Aller, R. Greenwood, R. Nicholas, P. M. Keller, W. E. DeWolf, Jr., F. Fan, D. J. Payne, and D. D. Jaworski. 2001. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48(1):1-6.
31. Stewart, M. J., S. Parikh, X. Guoping, P. J. Tonge, and C. Kisker. 1999. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Med. Biol. 290:859-865.
32. Suguna, K., A. Surolia, and N. Surolia. 2001. Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum. Biochem. Biophys. Res. Commun. 283:224-228.
33. Surolia, N., and A. Surolia. 2001. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 7:167-173. (Erratum, 7:636.)
34. Szkaradkiewicz, A., and T. Tulecka. 1998. Tumor necrosis factor alpha (TNF-alpha) production in experimental infection with Staphylococcus epidermidis. Med. Sci. Monit. 4:53-56.
35. Thomas, C. J., N. Surolia, and A. Surolia. 2001. Kinetic and thermodynamic analysis of the interactions of 23-residue peptides with endotoxin. J. Biol. Chem. 276:35701-35706.
36. Trinder, P. 1969. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J. Clin. Pathol. 22:158-161.
37. Tulp, M. T., G. Sundstrom, L. B. Martron, and O. Hutzinger. 1979. Metabolism of chlorodiphenyl ethers and Irgasan DP 300. Xenobiotica 9:65-77.
38. Turnowsky, F., K. Fuchs, C. Jeschek, and G. Högenauer. 1989. envM genes of Salmonella typhimurium and Escherichia coli. J. Bacteriol. 171: 6555-6565.
39. Villalain, J., C. R. Mateo, F. J. Aranda, S. Shapiro, and V. Micol. 2001. Membranotropic effects of the antibacterial agent triclosan. Arch. Biochem. Biophys. 390:128-136.
40. Walker, C. B., D. Nitzan, and T. D. Wilkins. 1977. Chemotherapy of an experimental Bacteriodes fragilis infection in mice. Antimicrob. Agents Chemother. 11:435-440.
41. Webster, D. 1977. The immediate reaction between bromocresol green and serum as a measure of albumin content. Clin. Chem. 23:663-665.
42. World Health Organization. 2002. WHO fact sheet no. 194, revised January 2002. [Online.] World Health Organization, Geneva, Switzerland. http://www.who.int/inf-fs/en/fact194.html.
43. Young, D. S., L. C. Pestaner, and V. Gibberman. 1975. Effects of drugs on clinical laboratory tests. Clin. Chem. 21(5):1D-432D.